NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
National Institutes of Health Clinical Center (CC)
Duke University
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
University of Illinois at Chicago
Washington University School of Medicine